Moderna, 2025

Moderna stock plunges 20% after company lowers 2025 sales forecast by $1 billion
Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half of the year.
Moderna cuts 2025 sales view on slow start to RSV shot, weak COVID vaccine demand
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow launch of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines.
Moderna shares tumble on slashed sales guidance
Moderna lost more than $3 billion in maker value after cutting its forecast for 2025 revenue from its COVID-19 and RSV vaccines.
Moderna Shares Drop to Five-Year Low After Slashing Revenue, Sales Forecasts
Moderna's stock plummeted to an almost five-year low after the biotech company cut its revenue outlook for this year and said that sales for last year will come in at the lower end of its guidance. Shares fell 22% to $33.07 in late morning trading Monday. The stock has tumbled 93% from its five-year high of $456.76 in August 2021.
Moderna cuts 2025 sales forecast by $1 billion on weak vaccine demand, shares fall
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its shares down more than 18% in premarket trading.
Moderna surprises the Street by predicting a bigger-than-expected sales drop
Shares of Moderna tumbled Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year.
Moderna shares drop 19% after 2025 revenue guidance falls below estimates
EST Moderna (MRNA) shares drop 19% after 2025 revenue guidance falls below estimatesStay Ahead of the Market:Discover outperforming
Moderna's $1 Billion Revenue Forecast Cut Sends Stock Plummeting Over 20%
Key Takeaways Moderna shares tumbled Monday after the company cut its 2025 revenue forecast by $1 billion.The company expects much of its revenue to be realized in the back half of the year from its Covid-19 and RSV vaccines.
Moderna Crashes 21%. 'No Inflection In Sight' After Guidance Cut, CMV Shortfall.
Moderna stock crashed Monday after the firm slashed its outlooks for 2024 and 2025, and announced an expanded cost-cutting ...
Moderna’s stock tumbles to post-COVID lows after revenue outlook disappoints
Moderna’s stock tumbles after a disappointing outlook for revenue and the need to accelerate its cost-cutting plan.
The Motley Fool on MSN1h
Why Moderna Stock Just Crashed 21%
Moderna 's ( MRNA -21.95%) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's ...
Moderna stock takes a 20% hit: here’s why
Moderna lowers its full-year sales guidance by up to $1.0 billion. Moderna stock is now down close to 30% versus its YTD high ...
FiercePharma2h
JPM25: Moderna slashes guidance, plots $1B in cost cuts this year amid lackluster vaccine sales
Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...
Top Stock Movers Now: Moderna, Macy's, Valero Energy, and More
U.S. equities were mixed at midday, with the Nasdaq losing more than 1% on worries about future Federal Reserve interest-rate ...
Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited) ...
A Norovirus Vaccine May Be Coming
“Commonly known as the stomach flu, norovirus has been around forever, and has become the leading cause of gastroenteritis or ...